Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Nature Medicine

Volumn 24, Issue 9, 2018, Pages 1449-1458

  Kim, Seung Tae ^a   Cristescu, Razvan ^b   Bass, Adam J ^c   Kim, Kyoung Mee ^a   Odegaard, Justin I ^d   Kim, Kyung ^a   Liu, Xiao Qiao ^b   Sher, Xinwei ^b   Jung, Hun ^b   Lee, Mijin ^a   Lee, Sujin ^a   Park, Se Hoon ^a   Park, Joon Oh ^a   Park, Young Suk ^a   Lim, Ho Yeong ^a   Lee, Hyuk ^a   Choi, Mingew ^a   Talasaz, AmirAli ^d   Kang, Peter Soonmo ^b   Cheng, Jonathan ^b   Loboda, Andrey ^b   Lee, Jeeyun ^a   Kang, Won Ki ^a   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b MERCK RESEARCH LABORATORIES   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Guardant Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; MUTL PROTEIN HOMOLOG 1; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL OUTCOME; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS INHIBITION; MICROSATELLITE INSTABILITY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MUTATIONAL LOAD; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMACH CANCER; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; STOMACH TUMOR; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CIRCULATING TUMOR DNA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PATIENT SELECTION; PROGRAMMED CELL DEATH 1 RECEPTOR; STOMACH NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85049969565     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-018-0101-z     Document Type: Article

References (37)

1. Bass, A. J. et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014)
2. Station, W. (ed) Keytruda (Pembrolizumab) Injection, for Intravenous Use (Merck & Co., 2015)
3. Fuchs, C. S. et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J. Clin. Oncol. 35, 4003–4003 (2017)
4. Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461–2471 (2017)
5. Muro, K. et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol. 17, 717–726 (2016)
6. Fuchs, C. S. et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J. Clin. Oncol. 35, 4003–4003 (2017)
7. Derks, S. et al. Abundant PD-L1 expression in Epstein–Barr virus-infected gastric cancers. Oncotarget 7, 32925–32932 (2016)
8. Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956–965 (2016)
9. Shah, M. A. et al. Molecular classification of gastric cancer: A new paradigm. Clin. Cancer Res. 17, 2693–2701 (2011)
10. Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017)
11. Razvan Cristescu, R. M. et al. Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab. J. Clin. Oncol. 35, suppl no. 7 (2017)
12. Cristescu, R. et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21, 449–456 (2015)
13. Cho, J. et al. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget 8, 13320–13328 (2017)
14. Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016)
15. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013)
16. Watanabe, T. et al. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res. 66, 9804–9808 (2006)
17. Cibulskis, K. et al. (2013) Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219
18. Mariathasan, S. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018)
19. Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016)
20. Kuziora, M. & Ranade, K. Circulating tumor DNA (ctDNA) variant allele frequencies are reduced in responders to durvalumab and low baseline variant allele frequencies are associated with improved overall survival in NSCLC patients. Cancer Res. 77, abstr. 582 (2017)
21. Kuziora, M. et al. Early reduction in circulating tumor DNA is associated with survival of urothelial carcinoma patients treated with durvalumab. J. Clin. Oncol. abstr. 11538, 36 (2017)
22. Stephane Terry, P. S. et al. New insights into the role of EMT in tumor immune escape. Mol. Oncol. 11, 824–846 (2017)
23. Lee, J. et al. Development of mesenchymal subtype gene signature for clinical application in gastric cancer. Oncotarget 8, 66305–66315 (2017)
24. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009)
25. Interpretation Manual—Gastric or Gastroesophageal Junction Adenocarcinoma. Vol. 2018 (Agilent, 2018)
26. Song, H. J. et al. Host inflammatory response predicts survival of patients with Epstein–Barr virus-associated gastric carcinoma. Gastroenterology 139, 84–92.e82 (2010)
27. Lanman, R. B. et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One 10, e0140712 (2015)
28. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009)
29. McKenna, A. et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010)
30. Sherry, S. T., Ward, M. & Sirotkin, K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res. 9, 677–679 (1999)
31. Forbes, S. A. et al. (2010) COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38, D652–D657
32. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016)
33. Salipante, S. J., Scroggins, S. M., Hampel, H. L., Turner, E. H. & Pritchard, C. C. (2014) Microsatellite instability detection by next generation sequencing. Clin. Chem. 60, 1192–1199
34. Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. (2016) DeconstructSigs: Delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31
35. Nevins, J. R. et al. Towards integrated clinico-genomic models for personalized medicine: Combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum. Mol. Genet. 12, R153–R157 (2003)
36. Coppola, D. et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 179, 37–45 (2011)
37. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012)